LT3444268T - Staphylococcus aureus leukocidinai, terapinės kompozicijos ir jų panaudojimo būdai - Google Patents

Staphylococcus aureus leukocidinai, terapinės kompozicijos ir jų panaudojimo būdai

Info

Publication number: LT3444268T
Authority: LT; Lithuania
Prior art keywords: leukocidines; staphylococcus aureus; therapeutic compositions; therapeutic; compositions
Prior art date: 2010-05-05

Application number

LTEP18196549.2T

Other languages

English (en)

Inventor

Victor J Torres

Ashley L DUMONT

Original Assignee

New York University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-05-05

Filing date

2011-05-05

Publication date

2022-04-11

2011-05-05 Application filed by New York University filed Critical New York University

2022-04-11 Publication of LT3444268T publication Critical patent/LT3444268T/lt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56938—Staphylococcus
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
- G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Physics & Mathematics (AREA)
Biotechnology (AREA)
Analytical Chemistry (AREA)
Epidemiology (AREA)
Zoology (AREA)
Food Science & Technology (AREA)
Cell Biology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Tropical Medicine & Parasitology (AREA)
Toxicology (AREA)
Wood Science & Technology (AREA)
Virology (AREA)
Dermatology (AREA)

LTEP18196549.2T 2010-05-05 2011-05-05 Staphylococcus aureus leukocidinai, terapinės kompozicijos ir jų panaudojimo būdai LT3444268T (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US33155010P	2010-05-05	2010-05-05

Publications (1)

Publication Number	Publication Date
LT3444268T true LT3444268T (lt)	2022-04-11

Family

ID=44902083

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP18196549.2T LT3444268T (lt)	2010-05-05	2011-05-05	Staphylococcus aureus leukocidinai, terapinės kompozicijos ir jų panaudojimo būdai

Country Status (21)

Country	Link
US (5)	US9783582B2 (lt)
EP (4)	EP3444268B1 (lt)
JP (4)	JP6031029B2 (lt)
KR (3)	KR20190133290A (lt)
CN (2)	CN103025352B (lt)
AU (5)	AU2011247989C1 (lt)
BR (1)	BR112012029521A2 (lt)
CA (2)	CA3088918A1 (lt)
DK (1)	DK3444268T3 (lt)
ES (2)	ES2904314T3 (lt)
HR (1)	HRP20220068T1 (lt)
HU (1)	HUE058787T2 (lt)
IL (2)	IL274109B2 (lt)
LT (1)	LT3444268T (lt)
MX (4)	MX2012012859A (lt)
MY (1)	MY165618A (lt)
PL (1)	PL3444268T3 (lt)
RU (2)	RU2677140C1 (lt)
SI (1)	SI3444268T1 (lt)
WO (1)	WO2011140337A2 (lt)
ZA (4)	ZA201208455B (lt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2677140C1 (ru)	2010-05-05	2019-01-15	Нью-Йорк Юниверсити	Лейкоцидины staphylococcus aureus, терапевтические композиции и их применение
MX357938B (es) *	2011-06-19	2018-07-31	Univ New York	Metodos para tratar y prevenir infecciones por staphylococcus aureus y afecciones asociadas.
AU2013251165B2 (en)	2012-04-17	2017-08-24	Arsanis Biosciences Gmbh	Cross-reactive Staphylococcus aureus antibody
US9657103B2 (en)	2012-05-02	2017-05-23	New York University	Methods of treating and preventing Staphylococcus aureus infections and associated conditions
KR101826538B1 (ko) *	2012-05-30	2018-02-07	현대자동차 주식회사	차량용 글래스 몰딩 부착 장치 및 그 방법
US20160108106A1 (en) *	2013-05-21	2016-04-21	Arsanis Biosciences Gmbh	Generation of highly potent antibodies neutralizing the lukgh (lukab) toxin of staphylococcus aureus
WO2014205127A2 (en)	2013-06-18	2014-12-24	New York University	Cellular factors involved in the cytotoxicity of staphylococcus aureus leukocidins: novel therapeutic targets
EP3057989A1 (en) *	2013-10-17	2016-08-24	ARSANIS Biosciences GmbH	Cross-reactive staphylococcus aureus antibody sequences
MX2016007533A (es)	2013-12-09	2016-12-14	Univ New York	Composiciones y metodos para el suministro fagocitico de agentes anti-estafilococicos.
MX2016007212A (es) *	2013-12-19	2016-09-07	Arsanis Biosciences Gmbh	Anticuerpos dirigidos contra la toxina lukgh (lukab) de staphylococcus aureus y secuencias de anticuerpos.
WO2016197071A1 (en) *	2015-06-05	2016-12-08	New York University	Compositions and methods for anti-staphylococcal biologic agents
WO2018165089A1 (en) *	2017-03-06	2018-09-13	Vanderbilt University	Human monoclonal antibodies to staphylococcus aureus lukab toxin
EP3638286A4 (en) *	2017-06-13	2021-03-10	Integrated Biotherapeutic Vaccines, Inc.	IMMUNOGENIC COMPOSITIONS CONTAINING POLYPEPTIDES DERIVED FROM LEUCOCIDINS LUKA AND LUKB OF STAPHYLOCOCCUS AUREUS
US20220241390A1 (en) *	2018-06-08	2022-08-04	Republic Of Korea (Animal And Plant Quarantine Agency)	Vaccine composition comprising recombinant protein of staphylococcus aureus attenuated enterotoxin and cytotoxin
KR102061735B1 (ko) *	2018-06-08	2020-01-02	대한민국(농림축산식품부 농림축산검역본부장)	황색포도알균 약독화 장독소 및 세포독소 재조합 단백질을 포함하는 백신 조성물
TWI902669B (zh)	2018-07-24	2025-11-01	美商麥迪紐有限責任公司	抗金黃色葡萄球菌凝集因子a(clfa)之抗體
CN113164602A (zh)	2018-10-09	2021-07-23	免疫医疗有限责任公司	抗金黄色葡萄球菌抗体的组合
MX2021004114A (es)	2018-10-09	2021-07-16	Medimmune Llc	Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus.
MX2021013833A (es)	2019-05-14	2022-03-17	Univ Chicago	Metodos y composiciones que comprenden variantes de la proteina a de estafilococos (spa).
MX2022004061A (es) *	2019-10-02	2022-07-19	Janssen Vaccines & Prevention Bv	Peptidos de estafilococo y metodos de uso.
KR20230091911A (ko) *	2020-09-28	2023-06-23	얀센 파마슈티칼즈, 인코포레이티드	변이체 스태필로코쿠스 아우레우스 LukA 및 LukB 폴리펩티드 및 백신 조성물
EP4313303A4 (en) *	2021-04-02	2025-02-26	Janssen Pharmaceuticals, Inc.	VACCINE COMPOSITIONS FROM STAPHYLOCOCCUS AUREUS
ES3002583A1 (es) *	2023-09-05	2025-03-07	Lopez Juan Luis Recio	Procedimiento de procesamiento de muestras biologicas para inmunoensayos

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US400A (en)		1837-09-25		Mode of causing puppet valves to work lights
US300A (en)		1837-07-29		Machine foe spinning woolen roving
RU2122862C1 (ru) *	1995-12-08	1998-12-10	Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова	Бесклеточная антистафилококковая вакцина для лечения хронической стафилококковой инфекции
AU6033299A (en)	1998-09-14	2000-04-03	Nabi	Compositions of beta-glucans and specific igiv
US20020061569A1 (en)	2000-03-21	2002-05-23	Robert Haselbeck	Identification of essential genes in prokaryotes
US6849259B2 (en)	2000-06-16	2005-02-01	Symphogen A/S	Polyclonal antibody composition for treating allergy
AT410798B (de) *	2001-01-26	2003-07-25	Cistem Biotechnologies Gmbh	Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0107661D0 (en) *	2001-03-27	2001-05-16	Chiron Spa	Staphylococcus aureus
CA2484604C (en)	2002-05-03	2011-08-02	Massachusetts Institute Of Technology	.delta. 4,5 glycuronidase and uses thereof
TWI374892B (en) *	2005-06-13	2012-10-21	Glaxosmithkline Biolog Sa	Use of panton-valentine leukocidin for treating and preventing staphylococcus infections
CN100485038C (zh) *	2005-09-13	2009-05-06	四川大学华西医院	小型化抗耐药金黄色葡萄球菌多肽及其应用与制备方法
WO2007100580A2 (en) *	2006-02-22	2007-09-07	The Texas A & M University System	Antibodies recognizing a highly expressed putative antigen of ca-mrsa and methods of use
EP2043690A1 (en) *	2006-06-12	2009-04-08	Nabi Biopharmaceuticals	Use of alpha-toxin for treating and preventing staphylococcus infections
CN101535811B (zh) *	2006-10-18	2016-05-04	生物梅里埃公司	用于体外诊断产pvl金黄色葡萄球菌的方法
GB0624340D0 (en) *	2006-12-06	2007-01-17	Nature Therapeutics Ltd	Antimicrobial composition
EP2185190B1 (en) *	2007-08-31	2015-06-24	University Of Chicago	Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
EP2215231A4 (en)	2007-10-15	2010-12-01	Univ Queensland	EXPRESSION SYSTEM FOR MODULATING AN IMMUNE RESPONSE
CN101182350A (zh) *	2007-11-02	2008-05-21	山东省农业科学院奶牛研究中心	金黄色葡萄球菌α-溶血素及其编码序列
WO2009111177A2 (en) *	2008-03-05	2009-09-11	Mount Sinai School Of Medicine Of New York University	Compositions and methods comprising genetically enhanced obligate and facultative anaerobic bacteria for oncopathic cancer therapy
WO2009140236A2 (en) *	2008-05-12	2009-11-19	Strox Biopharmaceuticals, Llc	Staphylococcus aureus-specific antibody preparations
WO2010098788A2 (en)	2008-08-25	2010-09-02	Amplimmune, Inc.	Pd-i antagonists and methods for treating infectious disease
CN103002911B (zh)	2008-09-26	2015-08-26	昂考梅德药品有限公司	卷曲蛋白结合药剂及其应用
MX2011010735A (es) *	2009-04-14	2012-01-25	Novartis Ag	Composiciones para inmunizacion contra staphylococcus aureus.
RU2677140C1 (ru) *	2010-05-05	2019-01-15	Нью-Йорк Юниверсити	Лейкоцидины staphylococcus aureus, терапевтические композиции и их применение

2011
- 2011-05-05 RU RU2018100393A patent/RU2677140C1/ru active
- 2011-05-05 EP EP18196549.2A patent/EP3444268B1/en active Active
- 2011-05-05 MY MYPI2012004840A patent/MY165618A/en unknown
- 2011-05-05 MX MX2012012859A patent/MX2012012859A/es unknown
- 2011-05-05 MX MX2019005156A patent/MX386545B/es unknown
- 2011-05-05 KR KR1020197034641A patent/KR20190133290A/ko not_active Ceased
- 2011-05-05 HU HUE18196549A patent/HUE058787T2/hu unknown
- 2011-05-05 DK DK18196549.2T patent/DK3444268T3/da active
- 2011-05-05 RU RU2012152086A patent/RU2644237C2/ru active
- 2011-05-05 KR KR1020187036903A patent/KR102050078B1/ko active Active
- 2011-05-05 ES ES18196549T patent/ES2904314T3/es active Active
- 2011-05-05 HR HRP20220068TT patent/HRP20220068T1/hr unknown
- 2011-05-05 MX MX2015016666A patent/MX364642B/es unknown
- 2011-05-05 US US13/696,245 patent/US9783582B2/en active Active - Reinstated
- 2011-05-05 SI SI201132036T patent/SI3444268T1/sl unknown
- 2011-05-05 CN CN201180033386.0A patent/CN103025352B/zh active Active
- 2011-05-05 JP JP2013509265A patent/JP6031029B2/ja active Active
- 2011-05-05 ES ES11778343.1T patent/ES2605476T3/es active Active
- 2011-05-05 EP EP16187485.4A patent/EP3121191B1/en not_active Not-in-force
- 2011-05-05 US US13/101,525 patent/US8431687B2/en not_active Expired - Fee Related
- 2011-05-05 CA CA3088918A patent/CA3088918A1/en active Pending
- 2011-05-05 EP EP21213876.2A patent/EP4015523A1/en active Pending
- 2011-05-05 BR BR112012029521-7A patent/BR112012029521A2/pt not_active Application Discontinuation
- 2011-05-05 CN CN201710442942.9A patent/CN107286224A/zh active Pending
- 2011-05-05 KR KR1020127031699A patent/KR101933226B1/ko active Active
- 2011-05-05 CA CA2798355A patent/CA2798355C/en active Active
- 2011-05-05 EP EP11778343.1A patent/EP2566519B1/en active Active
- 2011-05-05 AU AU2011247989A patent/AU2011247989C1/en active Active
- 2011-05-05 LT LTEP18196549.2T patent/LT3444268T/lt unknown
- 2011-05-05 PL PL18196549T patent/PL3444268T3/pl unknown
- 2011-05-05 IL IL274109A patent/IL274109B2/en unknown
- 2011-05-05 WO PCT/US2011/035354 patent/WO2011140337A2/en not_active Ceased
2012
- 2012-11-05 MX MX2021003906A patent/MX2021003906A/es unknown
- 2012-11-05 IL IL222874A patent/IL222874B/en active IP Right Grant
- 2012-11-09 ZA ZA2012/08455A patent/ZA201208455B/en unknown
2015
- 2015-02-23 AU AU2015200901A patent/AU2015200901B2/en not_active Ceased
2016
- 2016-05-09 ZA ZA2016/03107A patent/ZA201603107B/en unknown
- 2016-10-21 JP JP2016206490A patent/JP6253742B2/ja not_active Expired - Fee Related
- 2016-11-22 AU AU2016262661A patent/AU2016262661B2/en active Active
2017
- 2017-09-08 US US15/699,482 patent/US10316067B2/en active Active
- 2017-11-28 JP JP2017227313A patent/JP6678634B2/ja active Active
2018
- 2018-05-08 ZA ZA2018/02995A patent/ZA201802995B/en unknown
2019
- 2019-05-06 US US16/404,374 patent/US11584782B2/en active Active
- 2019-08-27 AU AU2019222824A patent/AU2019222824A1/en not_active Abandoned
- 2019-12-03 JP JP2019218457A patent/JP7001661B2/ja active Active
2020
- 2020-05-06 ZA ZA2020/02470A patent/ZA202002470B/en unknown
2021
- 2021-09-21 AU AU2021236457A patent/AU2021236457B2/en active Active
2023
- 2023-01-12 US US18/153,727 patent/US20230295248A1/en active Pending

Also Published As

Publication number	Publication date
RU2644237C2 (ru)	2018-02-08
AU2016262661B2 (en)	2019-07-25
EP2566519A2 (en)	2013-03-13
IL274109A (en)	2020-06-30
IL274109B1 (en)	2025-08-01
EP3121191A1 (en)	2017-01-25
CA2798355A1 (en)	2011-11-10
AU2011247989C1 (en)	2015-05-14
JP7001661B2 (ja)	2022-02-21
ES2605476T3 (es)	2017-03-14
JP6031029B2 (ja)	2016-11-24
WO2011140337A3 (en)	2012-03-15
KR20190133290A (ko)	2019-12-02
KR101933226B1 (ko)	2018-12-28
KR102050078B1 (ko)	2019-11-28
AU2021236457A1 (en)	2021-10-14
CN103025352A (zh)	2013-04-03
US20230295248A1 (en)	2023-09-21
SI3444268T1 (sl)	2022-05-31
IL222874B (en)	2020-05-31
MY165618A (en)	2018-04-18
WO2011140337A2 (en)	2011-11-10
ZA202002470B (en)	2022-12-21
US11584782B2 (en)	2023-02-21
JP6253742B2 (ja)	2017-12-27
EP3444268A1 (en)	2019-02-20
ES2904314T3 (es)	2022-04-04
US20180099998A1 (en)	2018-04-12
IL222874A0 (en)	2012-12-31
JP2018076324A (ja)	2018-05-17
RU2677140C1 (ru)	2019-01-15
MX364642B (es)	2019-05-03
US20130095115A1 (en)	2013-04-18
RU2012152086A (ru)	2014-06-10
HRP20220068T1 (hr)	2022-04-15
EP3444268B1 (en)	2021-12-15
AU2015200901B2 (en)	2016-12-15
US20190330284A1 (en)	2019-10-31
JP2017048206A (ja)	2017-03-09
BR112012029521A2 (pt)	2018-03-06
MX386545B (es)	2025-03-19
EP2566519A4 (en)	2014-01-15
KR20180137612A (ko)	2018-12-27
AU2016262661A1 (en)	2016-12-08
AU2011247989B2 (en)	2014-11-27
JP6678634B2 (ja)	2020-04-08
HUE058787T2 (hu)	2022-09-28
ZA201208455B (en)	2016-07-27
US20110274693A1 (en)	2011-11-10
ZA201603107B (en)	2018-09-26
CN107286224A (zh)	2017-10-24
AU2015200901A1 (en)	2015-03-12
IL274109B2 (en)	2025-12-01
ZA201802995B (en)	2020-12-23
JP2013531620A (ja)	2013-08-08
US8431687B2 (en)	2013-04-30
RU2018146933A (ru)	2020-06-29
KR20130060230A (ko)	2013-06-07
MX2019005156A (es)	2019-08-05
AU2021236457B2 (en)	2024-05-02
MX2021003906A (es)	2021-09-30
EP2566519B1 (en)	2016-09-07
DK3444268T3 (da)	2022-01-31
US10316067B2 (en)	2019-06-11
CN103025352B (zh)	2017-07-11
CA2798355C (en)	2020-09-15
EP4015523A1 (en)	2022-06-22
JP2020055835A (ja)	2020-04-09
AU2019222824A1 (en)	2019-09-19
AU2011247989A1 (en)	2012-12-06
US9783582B2 (en)	2017-10-10
CA3088918A1 (en)	2011-11-10
PL3444268T3 (pl)	2022-04-19
MX2012012859A (es)	2013-03-20
EP3121191B1 (en)	2018-09-26

Publication	Publication Date	Title
ZA202002470B (en)	2022-12-21	Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof
LT3202460T (lt)	2019-10-10	Arilmetoksi izoindolino dariniai ir kompozicijos, apimantys ir jų panaudojimo būdus
EP2611310A4 (en)	2014-04-16	ANTIMICROBIAL FORMULATION
EP2549993A4 (en)	2014-08-06	ANTIMICROBIAL COMPOSITIONS
BR112013011844A2 (pt)	2016-07-12	composições pesticidas agrícolas
EP2941128C0 (en)	2023-06-28	ANTIMICROBIAL COMPOSITIONS
LT3061454T (lt)	2021-05-10	Paraziticidinės peroralinės veterinarinės kompozicijos, apimančios sistemiškai veikiančius veikliuosius agentus, būdai ir jų panaudojimas
EP2725900A4 (en)	2015-08-05	ANTIMICROBIAL COMPOSITION
EP2558132A4 (en)	2015-12-23	ANTIMICROBIAL GEL
EP2911507A4 (en)	2016-11-09	AGRICULTURAL PESTICIDE COMPOSITIONS
PL3043769T3 (pl)	2023-10-23	Hipertoniczne, terapeutyczne kompozycje przeciwdrobnoustrojowe
EP2934121A4 (en)	2016-07-20	IMPROVED ANTIMICROBIAL COMPOSITIONS
EP2755476A4 (en)	2014-12-17	AGRICULTURAL PESTICIDE COMPOSITIONS
PL2547361T3 (pl)	2021-02-22	Bakteryjne składniki szczepionek pochodzące ze staphylococcus aureus i ich zastosowania
EP2627172A4 (en)	2014-11-05	ANTIMICROBIAL COMPOSITION
BR112014005254A2 (pt)	2017-04-04	composições antimicrobianas e usos das mesmas
BR112012013182A2 (pt)	2015-09-15	composições tópicas germicidas
IL225495B (en)	2018-07-31	Antimicrobial protein
EP2605654A4 (en)	2014-01-22	ANTIMICROBIAL COMPOSITIONS
EP2593134A4 (en)	2014-05-21	PROTECTION BASED ON THE STAPHYLOCOCCUS AUREUS PROTEIN SA2412
HK1182925A (en)	2013-12-13	Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof
FI20105517A0 (fi)	2010-05-11	Antimikrobinen koostumus
DK2558132T3 (da)	2021-01-18	Antimikrobiel gel
TH149336B (th)	2016-04-26	"องค์ประกอบต้านจุลชีพ"
TH149319B (th)	2016-04-26	"องค์ประกอบต้านจุลชีพ"